RATIONALE: Several studies suggest that nasal nitric oxide (nNO) measurement could be a test for primary ciliary dyskinesia (PCD), but the procedure and interpretation have not been standardized. OBJECTIVES: To use a standard protocol for measuring nNO to establish a disease-specific cutoff value at one site, and then validate at six other sites. METHODS: At the lead site, nNO was prospectively measured in individuals later confirmed to have PCD by ciliary ultrastructural defects (n = 143) or DNAH11 mutations (n = 6); and in 78 healthy and 146 disease control subjects, including individuals with asthma (n = 37), cystic fibrosis (n = 77), and chronic obstructive pulmonary disease (n = 32). A disease-specific cutoff value was determined, using generalized estimating equations (GEEs). Six other sites prospectively measured nNO in 155 consecutive individuals enrolled for evaluation for possible PCD. MEASUREMENTS AND MAIN RESULTS: At the lead site, nNO values in PCD (mean ± standard deviation, 20.7 ± 24.1 nl/min; range, 1.5-207.3 nl/min) only rarely overlapped with the nNO values of healthy control subjects (304.6 ± 118.8; 125.5-867.0 nl/min), asthma (267.8 ± 103.2; 125.0-589.7 nl/min), or chronic obstructive pulmonary disease (223.7 ± 87.1; 109.7-449.1 nl/min); however, there was overlap with cystic fibrosis (134.0 ± 73.5; 15.6-386.1 nl/min). The disease-specific nNO cutoff value was defined at 77 nl/minute (sensitivity, 0.98; specificity, >0.999). At six other sites, this cutoff identified 70 of the 71 (98.6%) participants with confirmed PCD. CONCLUSIONS: Using a standardized protocol in multicenter studies, nNO measurement accurately identifies individuals with PCD, and supports its usefulness as a test to support the clinical diagnosis of PCD.
RATIONALE: Several studies suggest that nasal nitric oxide (nNO) measurement could be a test for primary ciliary dyskinesia (PCD), but the procedure and interpretation have not been standardized. OBJECTIVES: To use a standard protocol for measuring nNO to establish a disease-specific cutoff value at one site, and then validate at six other sites. METHODS: At the lead site, nNO was prospectively measured in individuals later confirmed to have PCD by ciliary ultrastructural defects (n = 143) or DNAH11 mutations (n = 6); and in 78 healthy and 146 disease control subjects, including individuals with asthma (n = 37), cystic fibrosis (n = 77), and chronic obstructive pulmonary disease (n = 32). A disease-specific cutoff value was determined, using generalized estimating equations (GEEs). Six other sites prospectively measured nNO in 155 consecutive individuals enrolled for evaluation for possible PCD. MEASUREMENTS AND MAIN RESULTS: At the lead site, nNO values in PCD (mean ± standard deviation, 20.7 ± 24.1 nl/min; range, 1.5-207.3 nl/min) only rarely overlapped with the nNO values of healthy control subjects (304.6 ± 118.8; 125.5-867.0 nl/min), asthma (267.8 ± 103.2; 125.0-589.7 nl/min), or chronic obstructive pulmonary disease (223.7 ± 87.1; 109.7-449.1 nl/min); however, there was overlap with cystic fibrosis (134.0 ± 73.5; 15.6-386.1 nl/min). The disease-specific nNO cutoff value was defined at 77 nl/minute (sensitivity, 0.98; specificity, >0.999). At six other sites, this cutoff identified 70 of the 71 (98.6%) participants with confirmed PCD. CONCLUSIONS: Using a standardized protocol in multicenter studies, nNO measurement accurately identifies individuals with PCD, and supports its usefulness as a test to support the clinical diagnosis of PCD.
Authors: Hauw Lie; Maimoona A Zariwala; Cynthia Helms; Anne M Bowcock; John L Carson; David E Brown; Milan J Hazucha; James Forsen; David Molter; Michael R Knowles; Margaret W Leigh; Thomas W Ferkol Journal: J Pediatr Date: 2010-03-29 Impact factor: 4.406
Authors: Niki Tomas Loges; Heike Olbrich; Anita Becker-Heck; Karsten Häffner; Angelina Heer; Christina Reinhard; Miriam Schmidts; Andreas Kispert; Maimoona A Zariwala; Margaret W Leigh; Michael R Knowles; Hanswalter Zentgraf; Horst Seithe; Gudrun Nürnberg; Peter Nürnberg; Richard Reinhardt; Heymut Omran Journal: Am J Hum Genet Date: 2009-12 Impact factor: 11.025
Authors: A Barbato; T Frischer; C E Kuehni; D Snijders; I Azevedo; G Baktai; L Bartoloni; E Eber; A Escribano; E Haarman; B Hesselmar; C Hogg; M Jorissen; J Lucas; K G Nielsen; C O'Callaghan; H Omran; P Pohunek; M-P F Strippoli; A Bush Journal: Eur Respir J Date: 2009-12 Impact factor: 16.671
Authors: Jonathan S Berg; James P Evans; Margaret W Leigh; Heymut Omran; Chris Bizon; Ketan Mane; Michael R Knowles; Karen E Weck; Maimoona A Zariwala Journal: Genet Med Date: 2011-03 Impact factor: 8.822
Authors: Adam J Shapiro; Karen E Weck; Kay C Chao; Margaret Rosenfeld; Anders O H Nygren; Michael R Knowles; Margaret W Leigh; Maimoona A Zariwala Journal: J Pediatr Date: 2014-07-25 Impact factor: 4.406
Authors: Stephanie D Davis; Thomas W Ferkol; Margaret Rosenfeld; Hye-Seung Lee; Sharon D Dell; Scott D Sagel; Carlos Milla; Maimoona A Zariwala; Jessica E Pittman; Adam J Shapiro; Johnny L Carson; Jeffrey P Krischer; Milan J Hazucha; Matthew L Cooper; Michael R Knowles; Margaret W Leigh Journal: Am J Respir Crit Care Med Date: 2015-02-01 Impact factor: 21.405
Authors: Mahmoud R Fassad; Amelia Shoemark; Pierrick le Borgne; France Koll; Mitali Patel; Mellisa Dixon; Jane Hayward; Charlotte Richardson; Emily Frost; Lucy Jenkins; Thomas Cullup; Eddie M K Chung; Michel Lemullois; Anne Aubusson-Fleury; Claire Hogg; David R Mitchell; Anne-Marie Tassin; Hannah M Mitchison Journal: Am J Hum Genet Date: 2018-05-03 Impact factor: 11.025
Authors: Adam J Shapiro; Stephanie D Davis; Deepika Polineni; Michele Manion; Margaret Rosenfeld; Sharon D Dell; Mark A Chilvers; Thomas W Ferkol; Maimoona A Zariwala; Scott D Sagel; Maureen Josephson; Lucy Morgan; Ozge Yilmaz; Kenneth N Olivier; Carlos Milla; Jessica E Pittman; M Leigh Anne Daniels; Marcus Herbert Jones; Ibrahim A Janahi; Stephanie M Ware; Sam J Daniel; Matthew L Cooper; Lawrence M Nogee; Billy Anton; Tori Eastvold; Lynn Ehrne; Elena Guadagno; Michael R Knowles; Margaret W Leigh; Valery Lavergne Journal: Am J Respir Crit Care Med Date: 2018-06-15 Impact factor: 21.405
Authors: Timothy J Vece; Scott D Sagel; Maimoona A Zariwala; Kelli M Sullivan; Kimberlie A Burns; Susan K Dutcher; Roman Yusupov; Margaret W Leigh; Michael R Knowles Journal: Pediatr Pulmonol Date: 2019-09-23
Authors: Adam J Shapiro; Stephanie D Davis; Thomas Ferkol; Sharon D Dell; Margaret Rosenfeld; Kenneth N Olivier; Scott D Sagel; Carlos Milla; Maimoona A Zariwala; Whitney Wolf; Johnny L Carson; Milan J Hazucha; Kimberlie Burns; Blair Robinson; Michael R Knowles; Margaret W Leigh Journal: Chest Date: 2014-11 Impact factor: 9.410